{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:00:04Z","timestamp":1744164004026},"reference-count":36,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1567,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1111\/j.1365-2710.2011.01276.x","type":"journal-article","created":{"date-parts":[[2011,5,19]],"date-time":"2011-05-19T01:36:28Z","timestamp":1305768988000},"page":"173-181","source":"Crossref","is-referenced-by-count":23,"title":["Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease"],"prefix":"10.1155","volume":"37","author":[{"given":"L. B.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Vekeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,5,18]]},"reference":[{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/asheducation-2001.1.47","article-title":"Secondary iron overload","author":"Kushner","year":"2001","journal-title":"Education Program of the American Society of Hematology"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB3|cit3","unstructured":"Harvard Medical School Effects of iron overload: hemochromatosis, tranfusional iron overload http:\/\/sickle.bwh.harvard.edu\/index.html"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2001.03195.x","article-title":"Practical management of iron overload. Review","volume":"2","author":"Porter","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB7|cit7","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Heamatologica"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB8|cit8","doi-asserted-by":"crossref","unstructured":"Porter J Vichinsky E Rose C 2004 A phase II study with ICL670 (Exjade \u00ae ), a once-daily oral iron chelator, in patients with various transfusion-dependent anaemias and iron overload","DOI":"10.1182\/blood.V104.11.3193.3193"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/10428190701843221","article-title":"Iron overload in myelodysplastic syndromes","volume":"49","author":"Mahesh","year":"2008","journal-title":"Leukemia and Lymphoma"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB10|cit10","first-page":"1799","article-title":"Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis","volume":"20","author":"Shashaty","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB11|cit11","unstructured":"Deferasirox (Exjade \u00ae ) full prescribing information http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/exjade.pdf"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB12|cit12","first-page":"122","article-title":"Transfusion reactions in thalassemia. A survey from the Cooleycare programme. The Cooleycare Cooperative Group","volume":"75","author":"Rebulla","year":"1990","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0037-1963(01)90030-7","article-title":"Chelation therapy in beta-thalassemia: an optimistic update","volume":"38","author":"Giardina","year":"2001","journal-title":"Seminars in Hematology"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0145-2126(07)70462-9","article-title":"Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes","volume":"31","author":"Goldberg","year":"2007","journal-title":"Leukemia Research"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB15|cit15","first-page":"533","article-title":"Depression in sickle cell disease","volume":"95","author":"Hasan","year":"2003","journal-title":"Journal of the National Medical Association"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.thj.6200550","article-title":"Effectiveness and safety of combined iron chelation therapy with deferoxamine and deferiprone","volume":"5","author":"Alymara","year":"2004","journal-title":"The Hematology Journal"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","article-title":"The impact of iron overload and its treatment on quality of life: results from a literature review","volume":"4","author":"Abetz","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB18|cit18","unstructured":"Rofail D Muriel V Trudeau E et\u00a0al. 2006 Health-related quality of life is compromised in patients with iron overload receiving infusion treatment: US and UK SF-36 and CHQ scores compared with matched population norms"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clinical Therapeutic"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB20|cit20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1306.1306","article-title":"Satisfaction and adherence significantly improves in patients with beta-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade\u00ae)","author":"Porter","year":"2008a","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB21|cit21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1307.1307","article-title":"Improved health-related quality of life in patients with hematological disorders receiving deferasirox (Exjade\u00ae)","author":"Porter","year":"2008b","journal-title":"Blood"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB23|cit23","doi-asserted-by":"crossref","unstructured":"De Abreu Lourenco R Osborne R Dalton A et\u00a0al. 2005 An oral iron chelator and quality of life","DOI":"10.1182\/blood.V106.11.5553.5553"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB24|cit24","unstructured":"Delea TE Sofrygin O Baladi J-F et\u00a0al. 2006 Chelation therapy with deferasirox versus deferoxamine in transfusion-dependent sickle-cell disease: a cost effectiveness analysis from the US perspective"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1185\/03007990802077442","article-title":"Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom","volume":"24","author":"Karnon","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta13010","article-title":"Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation","volume":"13","author":"McLeod","year":"2009","journal-title":"Health Technology Assessment"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MPH.0b013e3181b53363","article-title":"Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy","volume":"31","author":"Alvarez","year":"2009","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/pbc.21929","article-title":"Oral iron chelation and the treatment of iron overload in a pediatric hematology center","volume":"52","author":"Raphael","year":"2009","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB29|cit29","doi-asserted-by":"crossref","unstructured":"Faris RJ McCrone D Mody-Patel N et\u00a0al. 2007 Compliance and persistency with a new oral iron chelator in patients with myelodysplastic syndromes","DOI":"10.1200\/jco.2007.25.18_suppl.17510"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ajem.2008.06.022","article-title":"Admission and length of stay due to painful vasoocclusive crisis in children","volume":"27","author":"Rogovik","year":"2009","journal-title":"American Journal of Emergency Medicine"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00115514-200809000-00006","article-title":"Sickle cell hospital unit: a disease-specific model","volume":"53","author":"Adams-Graves","year":"2008","journal-title":"Journal of Healthcare Management"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/pbc.21537","article-title":"Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease","volume":"51","author":"Raphael","year":"2008","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOP.0b013e328321882e","article-title":"Current Issues in blood transfusion for sickle cell disease","volume":"21","author":"Wahl","year":"2009","journal-title":"Current Opinion in Pediatrics"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB34|cit34","first-page":"61","article-title":"Evaluation of home desferal care in transfusion-dependent children with thalassemia and sickle cell disease (SCD)","volume":"4","author":"Weissman","year":"1997","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s002280000251","article-title":"Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiologic survey","volume":"56","author":"Arboretti","year":"2001","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2011.01276.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1111\/j.1537-2995.2007.01416.x","article-title":"Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review","volume":"47","author":"Delea","year":"2007","journal-title":"Transfusion"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2011.01276.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2011.01276.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:11Z","timestamp":1671818651000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2011.01276.x"}},"subtitle":["Compliance and persistence to deferoxamine vs. deferasirox"],"short-title":[],"issued":{"date-parts":[[2011,5,18]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01276.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,18]]}}}